Delpacibart eteddesiran

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameDelpacibart eteddesiran
Drug Alias NameAOC-Muscle atrophyMuscle atrophy antibody oligonucleotide conjugate therapy (Avidity Biosciences)del-desiranDelpacibart EtedesiranAOC-1001 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody-Oligonucleotide conjugate > Antibody-siRNA conjugate
Mechanisms of ActionMyotonin-protein kinase inhibitorsTransferrin receptor protein 1 binders
TargetsMyotonin-protein kinaseTransferrin receptor protein 1
Therapy Area/IndicationsGenetic Diseases, InbornNeuromuscular DiseasesMyotonia +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAvidity Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAvidity Biosciences Inc
Inactive CompaniesN/A
Active IndicationsGenetic Diseases, InbornNeuromuscular DiseasesMyotonia +[11] 
Inactive IndicationsNervous System DiseasesMusculoskeletal Diseases

Other Information

ATC CodeN/A
Related LinksN/A